Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Epigenic Therapeutics Raises $20 Million in Angel and Pre-A Rounds for Epigenetic Drugs

publication date: Aug 8, 2022

Shanghai Epigenic Therapeutics raised $20 million in Angel and Pre-A fundings to develop new therapies by using gene editing technology to regulate the epigenetic genome. Epigenetic changes do not change the DNA sequence, but they can change how an individual’s DNA sequence is read. Epigenic Therapeutics has developed a proprietary technology platform using artificial intelligence algorithms to obtain an optimized CRISPR-Cas component that regulates expression of target gene(s) without changing DNA. Morningside Venture Capital, Kingray Capital, Trinity Innovation Fund and TigerYeah Capital invested in the Pre-A funding while Angel investor FountainBridge Capital also participated. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here